US Stock MarketDetailed Quotes
HUMA Humacyte
- 5.100
- -0.080-1.54%
Close Jan 3 16:00 ET
- 5.120
- +0.020+0.38%
Post 20:01 ET
656.21MMarket Cap-3.81P/E (TTM)
5.250High5.010Low4.00MVolume5.130Open5.180Pre Close20.34MTurnover4.18%Turnover RatioLossP/E (Static)128.67MShares9.97052wk High-10.30P/B487.60MFloat Cap2.48052wk Low--Dividend TTM95.61MShs Float17.450Historical High--Div YieldTTM4.63%Amplitude1.960Historical Low5.090Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Humacyte Stock Forum
FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military.
The fact that we have a +10 billion $ runway is just nice to know.
Fresenius, with its stake and rights in Humacyte, could face a bidding war from Baxter, which seeks to expand its hemodialysis portfolio. Both see Humacyte’s innovative vascular technology as key to dominating the dialysis market.
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on watch for me, not an open po...
$Humacyte (HUMA.US)$
No comment yet